## William L Klein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3855125/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Alzheimer's disease-affected brain: Presence of oligomeric AÎ <sup>2</sup> ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10417-10422.	7.1	995
2	Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers. Journal of Neuroscience, 2004, 24, 10191-10200.	3.6	905
3	Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2273-2276.	7.1	790
4	Modeling Alzheimer's Disease with iPSCs Reveals Stress Phenotypes Associated with Intracellular Aβ and Differential Drug Responsiveness. Cell Stem Cell, 2013, 12, 487-496.	11.1	652
5	The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. Journal of Alzheimer's Disease, 2018, 64, S567-S610.	2.6	572
6	Self-Assembly of Aβ <sub>1</sub> <sub>-</sub> 42into Globular Neurotoxins. Biochemistry, 2003, 42, 12749-12760.	2.5	511
7	Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathologica, 2015, 129, 183-206.	7.7	490
8	Alzheimer's disease-type neuronal tau hyperphosphorylation induced by AÎ <sup>2</sup> oligomers. Neurobiology of Aging, 2008, 29, 1334-1347.	3.1	386
9	A Mouse Model of Amyloid β Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss <i>In Vivo</i> . Journal of Neuroscience, 2010, 30, 4845-4856.	3.6	348
10	Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease. Journal of Biological Chemistry, 2006, 281, 1599-1604.	3.4	342
11	Vaccination with soluble Aβ oligomers generates toxicityâ€neutralizing antibodies. Journal of Neurochemistry, 2001, 79, 595-605.	3.9	309
12	Monoclonal antibodies that target pathological assemblies of Aβ. Journal of Neurochemistry, 2007, 100, 23-35.	3.9	308
13	Alzheimer's Disease-Like Pathology Induced by Amyloid-Î <sup>2</sup> Oligomers in Nonhuman Primates. Journal of Neuroscience, 2014, 34, 13629-13643.	3.6	189
14	The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a nonâ€human primate model of Alzheimer's disease. Journal of Pathology, 2018, 245, 85-100.	4.5	180
15	Synaptotoxic Amyloid-β Oligomers: A Molecular Basis for the Cause, Diagnosis, and Treatment of Alzheimer's Disease?. Journal of Alzheimer's Disease, 2012, 33, S49-S65.	2.6	112
16	Synaptic targeting by Aβ oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease. , 2006, 2, 43-55.		103
17	Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers. Brain, 2016, 139, 1568-1586.	7.6	96
18	Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiology of Aging, 2012, 33, 825.e1-825.e13.	3.1	86

WILLIAM L KLEIN

#	Article	IF	CITATIONS
19	Amyloid-β and Tau Pathology of Alzheimer's Disease Induced by Diabetes in a Rabbit Animal Model. Journal of Alzheimer's Disease, 2012, 32, 291-305.	2.6	81
20	Iron Levels Modulate α‧ecretase Cleavage of Amyloid Precursor Protein. Journal of Neurochemistry, 1995, 64, 307-315.	3.9	80
21	Femtomole Immunodetection of Synthetic and Endogenous Amyloid-β Oligomers and Its Application to Alzheimer's Disease Drug Candidate Screening. Journal of Molecular Neuroscience, 2003, 20, 305-314.	2.3	77
22	Inhibition of Choline Acetyltransferase as a Mechanism for Cholinergic Dysfunction Induced by Amyloid-β Peptide Oligomers. Journal of Biological Chemistry, 2012, 287, 19377-19385.	3.4	77
23	Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6844-6854.	7.1	62
24	Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease. Frontiers in Neurology, 2019, 10, 1140.	2.4	46
25	Phosphorylated Tau Epitope of Alzheimer's Disease Is Coupled to Axon Development in the Avian Central Nervous System. Experimental Neurology, 1993, 120, 106-113.	4.1	45
26	Altered succinylation of mitochondrial proteins, APP and tau in Alzheimer's disease. Nature Communications, 2022, 13, 159.	12.8	42
27	Receptor-Mediated Increases in Phosphatidylinositol Turnover in Neuron-Like Cell Lines. Journal of Neurochemistry, 1983, 40, 547-554.	3.9	41
28	Protein kinase C and F-actin are essential for stimulation of neuronal FAK tyrosine phosphorylation by G-proteins and amyloid beta protein. FEBS Letters, 1996, 386, 185-188.	2.8	40
29	Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e237.	6.0	39
30	Specificity of Muscarinic Acetylcholine Receptor Regulation by Receptor Activity. Journal of Neurochemistry, 1981, 37, 1099-1108.	3.9	30
31	Glycoprotein Properties of Muscarinic Acetylcholine Receptors from Bovine Cerebral Cortex. Journal of Neurochemistry, 1986, 46, 23-32.	3.9	30
32	Parallel Postnatal Development of Choline Acetyltransferase Activity and Muscarinic Acetylcholine Receptors in the Rat Olfactory Bulb. Journal of Neurochemistry, 1986, 46, 671-680.	3.9	30
33	Targeting Generation of Antibodies Specific to Conformational Epitopes of Amyloid β-Derived Neurotoxins. CNS and Neurological Disorders - Drug Targets, 2009, 8, 65-81.	1.4	29
34	CNS neuronal focal adhesion kinase forms clusters that co-localize with vinculin. Journal of Neuroscience Research, 1996, 46, 445-455.	2.9	27
35	Identification of intraneuronal amyloid beta oligomers in locus coeruleus neurons of Alzheimer's patients and their potential impact on inhibitory neurotransmitter receptors and neuronal excitability. Neuropathology and Applied Neurobiology, 2021, 47, 488-505.	3.2	25

Rapid impact of ?-amyloid on Paxillin in a neural cell line. , 1997, 50, 979-989.

23

WILLIAM L KLEIN

#	Article	IF	CITATIONS
37	Alzheimer's Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station. Yale Journal of Biology and Medicine, 2017, 90, 45-61.	0.2	23
38	Induction of inverted morphology in brain organoids by vertical-mixing bioreactors. Communications Biology, 2021, 4, 1213.	4.4	13
39	Muscarinic Acetylcholine Receptors from Avian Retina and Heart Undergo Different Patterns of Molecular Maturation. Journal of Neurochemistry, 1988, 50, 1403-1411.	3.9	9
40	Insights into the mechanism of Alzheimer's β-amyloid aggregation as a function of concentration by using atomic force microscopy. Applied Physics Letters, 2012, 100, .	3.3	7
41	An Essential Role for Alzheimer's-Linked Amyloid Beta Oligomers in Neurodevelopment: Transient Expression of Multiple Proteoforms during Retina Histogenesis. International Journal of Molecular Sciences, 2022, 23, 2208.	4.1	5
42	Transient expression of adheron molecules during chick retinal development. Journal of Neurobiology, 1992, 23, 720-738.	3.6	3
43	Cholinergic differentiation in neurogenic basal forebrain cultures. Journal of Neurobiology, 1992, 23, 252-269.	3.6	1
44	Increased protein tyrosine phosphorylation in apoptotic neural cell death due to microtubule perturbations. Neurotoxicity Research, 2000, 2, 357-372.	2.7	0